RT Journal Article
SR Electronic
T1 Why so many significant Phase 3 results in clinical trials?
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 19001495
DO 10.1101/19001495
A1 Adda, Jérôme
A1 Decker, Christian
A1 Ottaviani, Marco
YR 2019
UL http://medrxiv.org/content/early/2019/07/12/19001495.abstract
AB Planning and execution of clinical research and publication of results should conform to the highest ethical standards, given that human lives are at stake. However, economic incentives can generate conflicts of interest for investigators, who may be inclined to withhold unfavorable results or even tamper with the data. Analyzing p-values reported to the ClinicalTrials.gov registry with two different methodologies, we find suspicious patterns only for results from trials conducted by smaller industry sponsors, with presumably less reputation at stake. First, a density discontinuity test reveals an upward jump at the classical threshold for statistical significance for Phase 3 results by small industry sponsors, suggesting some selective reporting. Second, we find an excess mass of significant results in Phase 3 compared to Phase 2. However, we can explain almost completely this excess mass for large industry sponsors, once we account for the incentives to selectively continue research through a novel technique linking trials across phases. In contrast, for trials sponsored by small pharmaceutical companies, selective continuation of trials economizing on research costs only explains one third of the increase in the number of significant results from Phase 2 to Phase 3. The different pattern depending on the type of sponsor suggests that reputational concerns can mitigate the short-run economic incentives that undermine integrity in reporting results of clinical research.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis is an observational study.Funding StatementThis research is funded by the European Research Council through Advanced Grant 295835 (Evalidea).Author DeclarationsAll relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.Not ApplicableAny clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.Not ApplicableThe study is based on publicly available data.https://clinicaltrials.gov